Compare Novo Nordisk A/S with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
DKK 1,050,614 Million ()
11.00
NA
3.76%
-0.23
52.79%
5.41
Revenue and Profits:
Net Sales:
79,144 Million
(Quarterly Results - Dec 2025)
Net Profit:
26,891 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
253.72%
0%
253.72%
6 Months
250.46%
0%
250.46%
1 Year
309.2%
0%
309.2%
2 Years
432.39%
0%
432.39%
3 Years
360.87%
0%
360.87%
4 Years
559.45%
0%
559.45%
5 Years
326.39%
0%
326.39%
Novo Nordisk A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.48%
EBIT Growth (5y)
18.98%
EBIT to Interest (avg)
18.19
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
1.66
Tax Ratio
20.93%
Dividend Payout Ratio
50.75%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
84.59%
ROE (avg)
69.89%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
5.73
EV to EBIT
9.45
EV to EBITDA
8.06
EV to Capital Employed
4.16
EV to Sales
3.91
PEG Ratio
7.58
Dividend Yield
3.55%
ROCE (Latest)
44.00%
ROE (Latest)
52.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 13 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
79,144.00
85,683.00
-7.63%
Operating Profit (PBDIT) excl Other Income
37,472.00
43,774.00
-14.40%
Interest
0.00
5,093.00
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
26,891.00
28,230.00
-4.74%
Operating Profit Margin (Excl OI)
403.20%
450.20%
-4.70%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -7.63% vs 30.09% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -4.74% vs 28.53% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
309,064.00
290,403.00
6.43%
Operating Profit (PBDIT) excl Other Income
149,685.00
147,948.00
1.17%
Interest
4,224.00
1,657.00
154.92%
Exceptional Items
-9,620.00
-6,204.00
-55.06%
Consolidate Net Profit
102,434.00
100,988.00
1.43%
Operating Profit Margin (Excl OI)
436.90%
480.00%
-4.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 6.43% vs 25.03% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 1.43% vs 20.68% in Dec 2024
About Novo Nordisk A/S 
Novo Nordisk A/S
Pharmaceuticals & Biotechnology
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Coordinates 
Company Details
Novo Alle 1 , BAGSVAERD None : 2880
Registrar Details






